Minireviews
Copyright ©2013 Baishideng Publishing Group Co.
World J Methodol. Dec 26, 2013; 3(4): 45-64
Published online Dec 26, 2013. doi: 10.5662/wjm.v3.i4.45
Table 2 Dosimetry aspects of different anticancer therapeutic agents under pre-clinical and clinical investigation
TherapeuticsDosimetry calculationsSpeciesTargeting tissuePathologyDose to tumor(mGy/MBq)Ref.
131I-HypOLINDA/EXM softwareRPLI ratsNecrotic tissueSolid tumors276–93600[79]
131I-Labeled TNT-1 monoclonal antibodyOrgan uptake-time integration by trapezoid method Whole body image analysisNude mice bearing ME-180 human cervical tumorsHistone fraction H1 in necrotic tissuesCervical carcinoma cell366–3610[31]
131I-m-iodobenzylguanidine (MIBG)MicroPET/CT 124I-MIBG OLINDA/EXM softwareMice bearing A431 human epithelial carcinoma xenograftsNorepinephrine transporterNeuroblastoma97–380[80]
131I- labeled monoclonal antibody MN-14MIRDOSE3 softwareNude mice with intraperitoneal LS174T tumorsCarcinoembryonic antigenPeritoneal metastases of colorectal origin-16200[89]
131I-tositumomabSPECT/CT Imaging DPM Monte Carlo electron and photon transport programHumansCD20-positive B-cellsRefractory B-cell NHL2.81 (mean)[81]
177Lu-DOTA-AE105Organ uptake-time integration by trapezoid method Sphere modelNude mice bearing colorectal HT-29 tumoruPAR-positive HT-29 xenograftColorectal cancer5.8[82]
177Lu-pertuzumabOrgan uptake-time integration by trapezoid method Sphere modelBALB/c (nu/nu) Mice with HER-2–overexpressing xenograftsHER-2 tyrosine kinase receptorBreast cancer-6900[83]
186Re-1-hydroxy- ethylidene-1,1 diphosphonic acidMIRDOSE 3.1 softwareHumansBone mineral metaboliteSkeletal metastases23–34[84]
90Y-ibritumomab tiuxetanPET/CT Imaging DPM 89Zr-ibritumomab tiuxetan OLINDA/EXM softwareHumansCD20-positive B-cellsRelapsing NHL8.6–28.6[85]
90Y- DOTA0-DPhe1-Tyr3- octreotideSPECT/CT Imaging DPM 111In-DOTA-TOCHumansSomatostatin receptor subtype 2NETs4-31 (mean 10)[86]